This article is more than 5 years old. Information may no longer be current.
VIDEO: Multi-target stool DNA test reliably detects colorectal cancer
Click Here to Manage Email Alerts
PHILADELPHIA – In this exclusive video perspective from the American College of Gastroenterology Annual Meeting, John B. Kisiel, MD, a gastroenterologist from the Mayo Clinic in Rochester, Minnesota, reviews the results of a multi-target stool DNA screening test for colorectal cancer in routine clinical practice.
“It’s very exciting to see that there are new people coming to participate in a colon-cancer screening program, including a significant number of people who are well-overdue to begin screening,” Kisiel told Healio Gastroenterology and Liver Disease.
Researchers at the Mayo Clinic followed approximately 1,000 patients who accepted screening with the tool starting in 2014. Nearly 900 of those patients met average risk screening criteria. Further, 40% of those who met at least an average risk score had never been screened before and most were aged 60 years or older.
Follow-up results showed that 30% of the screened patients had advanced adenomas and seven patients had cancers. Overall, approximately 11% of the patients were at an increased risk for colorectal cancer.
The total positive predictive value of the test for any colorectal neoplasm, advanced neoplasms, right-sided lesions and cancer among the patients with increased risk criteria was not significantly different than patients who had an average risk.
Similarly, the positive predictive value for any of the neoplasm categories was identical across different time strata among patients a few years out from a prior colonoscopy to those 11 or more years out.
“What this means is, roughly two in every three patients who were only zero to 5 years from their prior colonoscopy were found to have a polyp and one in four of these patients were found to have advanced adenomas,” Kisiel said. “This is a very striking finding that deserves further investigation as we find what incremental or additive benefit a stool DNA test might have in patients who are already receiving screening colonoscopy.”
Disclosure : Kisiel reports royalties or patents with Exact Sciences.